Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Bupropion / Varenicline for Smoking Cessation
NCT01303861Phase 3Completed
- Sponsor
- Duke University
- Start
- Mar 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupropion and varenicline in nicotine dependence (4 arms), sponsored by Duke University. Primary endpoint: Four-week Continuous Abstinence From Cigarette Smoking at Week 11. Started Mar 2011; status: completed.
02
Drugs
bupropionvarenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT01303861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303861.